Amgen Seeks Korean Partners in AI Drug Discovery, Obesity

Amgen's push for AI drug discovery partnerships in Korea, alongside its Golden Ticket program, reflects a strategic move to tap into the country's scientific talent. The company's prior success with LigaChem Biosciences in 2022 and mentorship with Intocell suggests a genuine interest in Korean biotech capabilities. This engagement could significantly boost Korea's AI in pharma sector, providing local startups with access to Amgen's resources and global network. The focus on AI and data science for drug development, especially in identifying new targets, aligns with global trends in pharmaceutical innovation. However, Amgen's late entry into the obesity drug market, dominated by Novo Nordisk and Eli Lilly, means its success in this area hinges on truly differentiated oral and long-acting treatments. While the company is open to external innovation, Korean partners will need to demonstrate strong scientific evidence and a clear path to addressing unmet patient needs. The challenge for Korean biotech firms will be to present solutions that offer a distinct competitive edge, beyond incremental improvements, to secure these high-value collaborations.